Analysts Set Bausch + Lomb Co. (NYSE:BLCO) PT at $18.82

Bausch + Lomb Co. (NYSE:BLCO - Get Free Report) has received an average recommendation of "Hold" from the twelve brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $18.82.

BLCO has been the topic of a number of research analyst reports. Stifel Nicolaus decreased their target price on Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating on the stock in a research note on Thursday, April 3rd. Royal Bank of Canada decreased their price objective on shares of Bausch + Lomb from $18.00 to $17.00 and set an "outperform" rating on the stock in a research report on Friday, April 4th. Wells Fargo & Company reiterated an "equal weight" rating and set a $15.00 target price (down from $24.00) on shares of Bausch + Lomb in a research report on Friday, March 28th. Needham & Company LLC reissued a "hold" rating on shares of Bausch + Lomb in a report on Thursday, February 20th. Finally, Bank of America dropped their price objective on shares of Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating for the company in a report on Thursday, February 20th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BLCO. Alberta Investment Management Corp boosted its holdings in Bausch + Lomb by 36.0% during the 4th quarter. Alberta Investment Management Corp now owns 3,008,193 shares of the company's stock valued at $54,328,000 after acquiring an additional 796,400 shares during the period. Whitebox Advisors LLC increased its stake in shares of Bausch + Lomb by 16.1% in the fourth quarter. Whitebox Advisors LLC now owns 1,443,101 shares of the company's stock worth $26,062,000 after buying an additional 199,856 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in Bausch + Lomb by 51.5% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,218,431 shares of the company's stock valued at $21,996,000 after buying an additional 414,138 shares during the last quarter. King Street Capital Management L.P. boosted its position in Bausch + Lomb by 55.2% during the 4th quarter. King Street Capital Management L.P. now owns 1,136,321 shares of the company's stock valued at $20,522,000 after buying an additional 404,256 shares during the period. Finally, Price T Rowe Associates Inc. MD bought a new stake in Bausch + Lomb in the 4th quarter worth $14,122,000. 11.07% of the stock is owned by institutional investors.

Bausch + Lomb Price Performance

NYSE:BLCO traded up $0.22 during mid-day trading on Tuesday, hitting $12.07. 845,194 shares of the stock traded hands, compared to its average volume of 618,799. The business's 50-day moving average price is $14.61 and its 200 day moving average price is $17.36. The company has a quick ratio of 1.01, a current ratio of 1.60 and a debt-to-equity ratio of 0.72. The company has a market cap of $4.26 billion, a PE ratio of -13.26, a price-to-earnings-growth ratio of 0.85 and a beta of 0.54. Bausch + Lomb has a 12-month low of $10.46 and a 12-month high of $21.69.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The company reported $0.25 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.02. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.26 billion. During the same period in the previous year, the business earned $0.24 EPS. The business's revenue for the quarter was up 9.1% on a year-over-year basis. On average, analysts expect that Bausch + Lomb will post 0.74 EPS for the current fiscal year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.